Chronic pain after thoracoscopic lung lobectomy
Conditions
Interventions
Oliceridine Group:Administer a loading dose of 0.03 mg/kg 20-30 minutes before the end of the surgery. The postoperative PCA analgesia pump configuration and parameters are as follows: 0.6 mg/kg Oxyco
Sufentanil Group:Administer a loading dose of 0.1 µg/kg 20-30 minutes before the end of the surgery. The postoperative PCA analgesia pump configuration and parameters are as follows: 2 µg/kg Sufentani
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1 Age between 18 and 75 years, ASA classification of I-III, BMI of 18-30 kg/m^m; 2 Scheduled to undergo unilateral video-assisted thoracoscopic lung resection (including wedge resection, segmentectomy, lobectomy, and radical lung cancer surgery); 3 Preoperative NRS score of less than 1; 4 Understand the content and objectives of this study, voluntarily agree to participate, and sign the informed consent form; 5 Expected to be able to return to the general ward postoperatively.
Exclusion criteria
Exclusion criteria: Preoperative Exclusion Criteria: 1 Patients with preoperative chronic pain or those who have been using analgesics long-term; 2 Patients who have previously undergone surgery on the same side of the chest; 3 Patients who have received radiotherapy or chemotherapy prior to surgery; 4 Patients with severe cardiovascular or cerebrovascular diseases, or abnormal liver and kidney function (ALT/AST > 3 times the upper limit; eGFR < 60 ml/min); 5 Patients with concurrent tumors and infections; 6 Patients with preexisting psychiatric disorders or language barriers that hinder cooperation with follow-up; 7 Patients with known allergies to the opioids, adjuvant analgesics, anesthetics, or antiemetics used in the study; 8 Other conditions considered unsuitable for enrollment by the investigator. Postoperative Rejection Criteria: 1 Patients who no longer meet the inclusion criteria after enrollment, such as those whose surgery is terminated for various reasons, converted to open surgery, or temporarily changed to bilateral surgery; 2 Patients who require further postoperative radiotherapy, chemotherapy, or hyperthermic perfusion treatment due to their medical condition; 3 Patients who experience severe complications such as reintubation or who are unable to be weaned off mechanical ventilation and return to the general ward; 4 Patients who experience serious adverse reactions during the perioperative period, such as anaphylactic shock, cardiac or respiratory arrest, myocardial infarction, or stroke; 5 Patients who develop wound infections, fat liquefaction, or require reoperation during the study period; 6 Patients who die or are unable to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of chronic pain (CPSP) 3 months after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chronic pain NRS score 3 months after surgery;incidence of adverse reactions;Acute pain NRS score at 24 and 48 hours after surgery;Consumption and frequency of rescue analgesics ;Neuropathic pain ;Pittsburgh Sleep Index (PSQI) ;Hamilton Anxiety/Depression (HAMA/HAMD) ;PCS pain catastrophizing scale;SF-36 quality of life ;Analgesia within 3 months after surgery; | — |
Countries
China
Contacts
Public ContactYu Yonghao
Tianjin Medical University General Hospital
Outcome results
None listed